(Q33770115)

29 July 2017

Quinolone activity against anaerobes (English)

1 reference

29 July 2017

Quinolone Activity Against Anaerobes (English)

0 references

0 references

Appelbaum PC

1

1 reference

29 July 2017

Peter C. Appelbaum

series ordinal

1

0 references

publication date

1 January 1999

1 reference

29 July 2017

1999

0 references

published in

Drugs

1 reference

29 July 2017

58 Suppl 2

1 reference

29 July 2017

58

0 references

page(s)

60-64

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199958002-00012

29 July 2017

Supplement 2

0 references

exact match

0 references

cites work

In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents

1 reference

12 December 2020

Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres

1 reference

12 December 2020

Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole

1 reference

12 December 2020

Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U

1 reference

12 December 2020

Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions

1 reference

12 December 2020

Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria

1 reference

12 December 2020

In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin

1 reference

12 December 2020

Reduction of oral flora with ciprofloxacin in healthy volunteers

1 reference

12 December 2020

Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals

1 reference

12 December 2020

In vitro activity of DU-6859a against anaerobic bacteria

1 reference

12 December 2020

Mechanisms of beta-lactam resistance in anaerobic bacteria.

1 reference

12 December 2020

Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes

1 reference

12 December 2020

Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology

1 reference

12 December 2020

Bay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria

1 reference

12 December 2020

Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group

1 reference

12 December 2020

Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria

1 reference

12 December 2020

Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

12 December 2020

In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones

1 reference

12 December 2020

Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses

1 reference

12 December 2020

Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam

1 reference

12 December 2020

Comparative in vitro activity of cefetamet and fleroxacin against anaerobic bacteria

1 reference

12 December 2020

In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867)

1 reference

12 December 2020

Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes

1 reference

12 December 2020

In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria

1 reference

12 December 2020

In vitro activities of three of the newer quinolones against anaerobic bacteria

1 reference

12 December 2020

Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.

1 reference

12 December 2020

Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.

1 reference

12 December 2020

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

12 December 2020

Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms

1 reference

12 December 2020

The killing action of fleroxacin upon Bacteroides fragilis

1 reference

12 December 2020

10.2165/00003495-199958002-00012

Identifiers

DOI

0 references

Dimensions Publication ID

0 references

1 reference